RHÖN-KLINIKUM has delivered a 30.3% share price gain over the past three years, which naturally puts the focus on whether that move is supported by the hospital operator's cash generation. With the stock recently closing at €14.50, the key issue now is how that market price lines up against what its cash flows suggest the business might be worth.

• The 30.3% return over three years puts real weight on the question of whether RHÖN-KLINIKUM's current valuation is grounded in its underlying cash flows.

• The hospital group's business model, which converts patient volumes and reimbursement rates into operating cash, can shape how quickly its future cash flows may support the current share price.

• If you'd rather focus on earnings, this one's for you. See why RHÖN-KLINIKUM's 23.1x P/E tells a different valuation story .

The stock's next move may depend on whether RHÖN-KLINIKUM's present market price is adequately explained by the intrinsic value indicated by its Discounted Cash Flow (DCF) estimate.

If you want more ideas alongside RHÖN-KLINIKUM while you assess whether current prices line up with its cash flows, a focused stock screen of 191 high quality undervalued stocks .

Where Does RHÖN-KLINIKUM Sit on Cash Flow?

The Discounted Cash Flow (DCF) approach here takes RHÖN-KLINIKUM's own free cash generation and discounts it back to today. Latest twelve month Free Cash Flow is about €36.3 million, and the model then projects a gradual rise in annual cash flows into the next decade rather than sharp swings.

Those projections are built on a 2 Stage Free Cash Flow to Equity framework, with analyst input for the nearer years and modest estimated growth rates after 2028. When those future streams are discounted and compared with the current share price of €14.50, the outcome suggests RHÖN-KLINIKUM's implied worth based on cash flows is broadly in line with what the market is already paying. Find out what RHÖN-KLINIKUM could be worth using our Discounted Cash Flow (DCF) estimate .

The RHÖN-KLINIKUM Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the RHÖN-KLINIKUM valuation puzzle leaves off, spelling out which paths for future growth, margins and earnings would need to play out for the equity to trade meaningfully above or below today's level. Rather than relying on a single multiple or DCF output, each narrative lays out the assumptions that sit behind its fair value view so you can track those expectations against the company's reported numbers over time on the Community page.